View Post

‘Unprecedented’ 73% Response Rate With Combo in Untreated RCC

In In The News by Barbara Jacoby

By: Nick Mulcahy From: medscape.com The combination of an immunotherapy and a vascular endothelial growth factor (VEGF) inhibitor resulted in a groundbreaking response rate in metastatic renal cell carcinoma (RCC), according to results of an ongoing phase 1b study. In a cohort of treatment-naive patients, 38 of 52 (73%) achieved an objective response, including 4 complete responses, with the combination …